Khushali Jhaveri, Assistant Professor of Medicine at IU Simon Comprehensive Cancer Center, shared a post on X:
“PROSPECT: Tirabrutinib in rrPCNSL (n=48)
– ORR 67%, CR/CRu 27%
– mPFS 6.0 mo; mOS NR
– 81% of patients on steroids at baseline had sustained dose ↓; 69% fully discontinued
– Well tolerated; low Gr ≥3 tox Encouraging monotherapy option in a tough setting.”
More posts featuring Khushali Jhaveri.
